Patents by Inventor C. Max Schmidt

C. Max Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160033510
    Abstract: Levels of VEGF-A, VEGF-C and PGE2 were measured in patient groups presenting with different types of pancreatic lesions. Pancreatic fluids that exhibited high levels of VEGF-A and relative low levels of VEGF-C correlated well with a diagnosis of serous cystadenoma. Pancreatic fluids collected from cysts in patients that did not have a clinical diagnosis of pancreatic cancer and that exhibited relatively low levels of VEGF-A correlated with a diagnosis of intraductal papillary mucinous neoplasms (IPMN). Furthermore, the level of PGE2 increased with dysplastic stage. Contacting pancreatic fluid with reagents that selectively bind to VEGF-A, VEGF-C and PGE2 provide a useful diagnostic tool for identifying patients with these benign, pre-malignant or malignant lesions of the pancreas.
    Type: Application
    Filed: April 1, 2015
    Publication date: February 4, 2016
    Inventors: C. Max Schmidt, Michele Yip-Schneider
  • Publication number: 20120231480
    Abstract: Levels of VEGF-A, VEGF-C and PGE2 were measured in patient groups presenting with different types of pancreatic lesions. Pancreatic fluids that exhibited high levels of VEGF-A and relative low levels of VEGF-C correlated well with a diagnosis of serous cystadenoma. Pancreatic fluids collected from cysts in patients that did not have a clinical diagnosis of pancreatic cancer and that exhibited relatively low levels of VEGF-A correlated with a diagnosis of intraductal papillary mucinous neo-plasms (IPMN). Furthermore, the level of PGE2 increased with dysplastic stage. Contacting pancreatic fluid with reagents that selectively bind to VEGF-A, VEGF-C and PGE2 provide a useful diagnostic tool for identifying patients with these benign, pre-malignant or malignant lesions of the pancreas.
    Type: Application
    Filed: August 27, 2010
    Publication date: September 13, 2012
    Applicant: Indiana University Research & Technology Corporation
    Inventors: C. Max Schmidt, Michele Yip-Schneider